Modified tRNA System for Nonsense Mutation Read-Through
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating hereditary diseases caused by nonsense mutations, such as Duchenne muscular dystrophy, are inadequate, with existing treatments like aminoglycosides causing adverse reactions and exon skipping methods facing toxicity concerns, and there is a need for a more effective way to read through premature termination codons to restore functional proteins.
Innovation Solution
A genetic code expansion technology using a modified tRNA system from Methanosarcina barkeri, specifically tRNAPyl, to introduce non-natural amino acids and read through stop codons UAG, UAA, and UGA, allowing for the restoration of truncated proteins by modifying the anticodon loop to UUA or UCA, enabling efficient read-through of nonsense mutations in hereditary diseases and cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical small molecule-induced read-through (aminoglycosides) is used to treat nonsense mutations, then premature termination codons can be suppressed, but serious adverse reactions (ototoxicity and nephrotoxicity) occur
Solution Approach 1:
The patent introduces an orthogonal tRNA synthetase system as an intermediary mechanism. The engineered tRNA (with modified anticodon loop UUA or UCA) and PylRS form a dedicated read-through system that competes with termination factors without requiring toxic small molecules. This intermediary system selectively suppresses PTCs through genetic code expansion, achieving read-through without the ototoxicity and nephrotoxicity associated with aminoglycosides
2Reliability
If exon skipping methods are used to treat Duchenne muscular dystrophy, then truncated proteins can be avoided, but toxicity concerns arise
Solution Approach 1:
Instead of skipping the problematic exon (exon skipping approach), the patent inverts the strategy by directly addressing the nonsense mutation within the exon. The engineered tRNA system reads through the premature termination codon, allowing complete protein synthesis including the originally mutated exon. This inversion approach restores full-length functional protein without the toxicity concerns of exon skipping therapies
3Reliability
If suppressor tRNA is used for read-through, then premature termination codons can be suppressed, but normal stop codons may be recognized causing potential toxicity
Solution Approach 1:
The patent applies local quality by engineering specific modifications only in the anticodon loop region (changing CUA to UUA or UCA) of the tRNA. This localized modification confers specificity for recognizing UAA and UGA stop codons while maintaining orthogonality with the host translation system. The modified tRNA competes effectively at PTC sites without broadly affecting normal stop codon function, thereby suppressing read-through toxicity while maintaining therapeutic efficacy
Data Source
AI summary
Provided is a method for high-efficiently reading through a nonsense mutation site in a pathogenic gene in a monogenic hereditary disease and restoring the normal structure and function of a mutant protein, by using a genetic code expanded non-natural amino acid system. By modifying a tRNA of Methanosarcina barkeri (tRNAPyl), an all-new UAA and UGA encoded non-natural amino acid system that has high read-through efficiency is obtained, and the range of using the orthogonal pair of tRNAPyl and pyrrolysyl-tRNA synthetase (PylRS) is expanded. A plasmid mimicking the endogenous premature termination codon is constructed, so as to evaluate the efficiency of reading through the endogenous premature termination codon. Also provided is a system mainly comprising pathogenic genes of monogenic hereditary diseases and tumor inhibitory genes in tumor cells.